Results 191 to 200 of about 3,143,393 (310)

Epigenome‐wide association study, meta‐analysis, and multiscore profiling of whole blood in Parkinson's disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objectives An increasing body of evidence indicates altered DNA methylation in Parkinson's disease, yet the reproducibility and utility of such methylation changes are largely unexplored. We aimed to further elucidate the role of dysregulated DNA methylation in Parkinson's disease and to evaluate the biomarker potential of methylation‐based ...
Ingeborg Haugesag Lie   +4 more
wiley   +1 more source

Relationship of cognitive decline with glucocerebrosidase activity and amyloid‐beta 42 in DLB and PD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objective Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including GBA1 and APOEε4 mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid‐beta 42 (Aβ42) levels, may hold potential as predictive ...
Maria Camila Gonzalez   +15 more
wiley   +1 more source

Handling rescue therapy in myasthenia gravis clinical trials: why it matters and why you should care

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Myasthenia gravis (MG) clinical trials typically allow rescue therapy during follow‐up in the event of marked worsening of MG symptoms. Failure to appropriately address rescue therapy in defining treatment effects and planning statistical analyses may yield biased estimates, increase false positive rates, or decrease statistical power – all of
Justin M. Leach   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy